Tebipenem pivoxil is an oral carbapenem antibacterial indicated for complicated urinary tract infections, including pyelonephritis, caused by susceptible Enterobacterales and Enterococcus faecalis in adults with limited or no alternative oral treatment options. Tebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis.
- Mechanism
- Curator reviewed · 4 references
Tebipenem pivoxil is a prodrug of tebipenem, a carbapenem antibacterial. The bactericidal action of tebipenem is mediated through binding to essential penicillin-binding proteins (PBPs). In Escherichia coli and Klebsiella pneumoniae, tebipenem has affinity for PBPs 1a, 1b, 2, 3, 4 and 5/6, with preferential binding to PBP 2. Inhibition of PBPs leads to disruption of cell wall biosynthesis.
- Primary indication
- Tebipenem pivoxil is indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis, in adult patients who have...Curator reviewed · 2 structured indications
- Formula / weight
- C22H31N3O6S2 · 497.63 g/mol (avg)
- First approval
- United States, 2026
- Code names
- L-084 · LJC-11084 · ME-1211
- Brand names
Resolves to
SNUDIPVBUUXCDG-QHSBEEBCSA-NSMILES[H][C@]12[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(=O)OCOC(=O)C(C)(C)CWhat you can answer from here — as of November 02, 2026
Which other approved drugs treat the same conditions as Tebipenem pivoxil, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account